文献速递免疫规划卫生政策与健康促进

为世界卫生组织预认证加强药物警戒能力:布坦坦研究所三价流感疫苗案例

Pharmacovigilance capacity strengthening for WHO prequalification: The case of the trivalent influenza vaccine manufactured by Instituto Butantan.
PubMed 文献 · Vaccine · 2019-10-04

布坦坦研究所为其三价流感疫苗申请世界卫生组织预认证,需提交药物警戒计划并证明药物警戒体系运行有效。文章描述了在PATH与美国BARDA支持下,通过改进组织结构、培训人员、完善流程与文件、获取符合E2B标准的药物警戒数据库等策略加强药物警戒能力的过程,最终建立了符合国际监管要求的药物警戒体系。

要点

  • 布坦坦研究所三价流感疫苗申请WHO预认证需提交药物警戒计划并证明体系运行有效。
  • 能力加强策略包括组织结构改进、人员培训、内部流程与程序完善、适当文件记录及获取E2B合规数据库。
  • 项目最终建立了符合国际监管要求的药物警戒体系。

核心结论

  • 该项目使布坦坦研究所建立了符合国际监管要求的药物警戒体系。

研究设计与样本

  • 本文描述布坦坦研究所为三价流感疫苗WHO预认证而开展药物警戒体系能力加强的过程,该过程由PATH与美国BARDA支持。

主要发现

  • 能力加强的关键战略轴包括组织结构改进、人力资源培训、内部流程与程序完善、适当文件记录以及获取符合E2B标准的药物警戒数据库。

关键数值与推荐

  • WHO预认证审查的一项关键要求是提交三价流感疫苗的药物警戒计划,包括主动监测评估,并证明布坦坦研究所药物警戒体系运行有效。

局限性

  • 原文未报告局限性

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

Instituto Butantan is a biomedical research center and vaccine manufacturer affiliated with the São Paulo State Secretary of Health in Brazil. In 2013, Instituto Butantan successfully licensed its trivalent influenza vaccine, in order to support the Brazilian National Immunization Program's influenza vaccination strategy, which was introduced in 1999. In order to respond to the increasing influenza vaccine demand worldwide, Instituto Butantan is undergoing prequalification of its trivalent influenza vaccine by the World Health Organization (WHO). A key requirement of the prequalification review was the submission of a pharmacovigilance plan, including an active surveillance evaluation, for the trivalent influenza vaccine, and proof of a functional pharmacovigilance system at Instituto Butantan. The aim of this paper is to describe the capacity strengthening process of the pharmacovigilance system at Instituto Butantan for the WHO prequalification of the trivalent influenza vaccine. This process was supported by PATH and the U.S. Federal Government Biomedical Advanced Research and Development Authority (BARDA). The key strategic axes for this capacity strengthening process included the improvement of organizational structure, human resources training, internal processes and procedures, appropriate documentation, and acquisition of an E2B compliant pharmacovigilance database. The project led to the establishment of a functional pharmacovigilance system compliant with international regulatory requirements.

来源:Vaccine,查看原文。版权归原作者所有。

引用

  1. Koike ME, Gattás VL, Lucchesi MBB, et al. Pharmacovigilance capacity strengthening for WHO prequalification: The case of the trivalent influenza vaccine manufactured by Instituto Butantan. Vaccine. 2019. PMID: 31590933. doi:10.1016/j.vaccine.2019.09.082

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。